The Index Valve Matters: Optimal Index TAVI for Patients Lifetime Management
In this interview, Prof Michael Joner (German Heart Centre, Munich, DE) discusses the specific needs and treatment considerations when managing low and intermediate risk TAVI patients. He also highlights the increasing need to consider future interventions when selecting the index valve.
Prof Joner details the Navitor TAVI system resheathable design with intra-annular function, large-cell frame for coronary re-access and dual sealing cuff to minimise paravalvular leak meeting the needs of patients with long life expectancy.
Finally he shares his experience on the optimal implantation technique to optimise the outcomes of low-intermediate risk patients when treated with the Navitor TAVI system.
Learning Objectives
- Understand the key treatment considerations for lifetime management of patients at low and intermediate risk
- Understand the impact of index valve selection on the feasibility of future interventions in patients with longer life expectancy
- Explore the impact of implantation technique in achieving optimal and durable clinical outcomes
Target Audience
- HCPs with interest in structural heart therapies, in particular aortic valve management
More from this programme
Part 1
The Index Valve Matters: Optimal Index TAVI for Patients Lifetime Management
Faculty Biographies
Michael Joner
Head of the Preclinical Research
Prof Michael Joner is DZHK Professor for Early Clinical Trials at the German Heart Centre in Munich, Germany. His main research focus is on findings novel diagnostic or therapeutic pathways to target atherosclerosis.
Prof Joner completed his medical training at the University of Wuerzburg in Würzburg, Germany. During his course, he went on to complete a 2-year fellowship in cardiovascular pathology under the lead of Prof Virmani in Washington DC.
Comments